

REGENERATIVE MEDICINES: BONE AND JOINT APPLICATIONS



PHM032C

Kevin Gainer
Project Analyst

ISBN: 1-56965-438-7

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
OBJECTIVES AND GOALS OF STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
STUDY SCOPE AND FORMAT	3
METHODOLOGY	4
INFORMATION SOURCES	4
ANALYST CREDENTIALS	4
RELATED BCC REPORTS	4
BCC ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2012-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW AND OVERALL STATUS OF THE INDUSTRY	10
TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET	10
ESTIMATED NUMBER OF COMPANIES IN REGENERATIVE SECTOR	10
<i>TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR</i>	11
SIZE OF ORTHOPEDIC SECTOR AND LEADING SUPPLIERS	12
<i>TABLE 2 2012 REVENUES FOR TOP SUPPLIERS OF ORTHOPEDIC PRODUCTS AND MATERIALS (\$ BILLIONS)</i>	12
HOW REGENERATIVE MEDICINE WORKS	12
TISSUES AND ORGANS ON DEMAND	13
ORGAN REPLACEMENT IS A \$100 BILLION PER YEAR BUSINESS	14
EXAMPLE IMPACT ON EXISTING CONDITIONS AND DISEASES	14
BARRIERS TO REGENERATIVE MEDICINE	14
<i>TABLE 3 TEN PRINCIPAL MARKET DRIVERS (RANKED, MOST SIGNIFICANT TO LEAST SIGNIFICANT)</i>	16
CURRENT R&D PRIORITIES	16
<i>TABLE 4 R&D FOCUSES FOR PRINCIPAL REGENERATIVE MEDICINE</i>	17
<i>TABLE 5 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS</i>	18
NATIONAL SCIENCE FOUNDATION PRIORITIES	18
<i>TABLE 6 NATIONAL SCIENCE FOUNDATION REGENERATIVE MEDICINE FUNDING PRIORITIES AS OF MAY 1, 2013 (\$)</i>	19
TOTAL OUTPUT OF THE SECTOR	19
REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS	20
POPULATION TRENDS	21
MARKET TIMING	21
OVERSEAS INITIATIVES	21
CHAPTER 4 PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE	24
HUMAN SUBSTANCES	25
CELLS AND TISSUES	25

TOPIC	PAGE NO.
TISSUE ENGINEERING	25
Importance of Scaffolding in Tissue Engineering	25
Plastic Scaffolding	26
Blood Vessel Scaffolding	27
Center for Integration of Medicine and Innovative Technology (CIMIT)	27
<i>TABLE 7 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2011</i>	27
Massachusetts General Hospital	28
Duke University Stem Cell and Regenerative Medicine Program	29
EMBRYONIC STEM CELLS	29
Therapeutic Cloning	29
ADULT STEM CELLS: JUST AS GOOD AS EMBRYONIC STEM CELLS	30
Genzyme	30
University of Minnesota Stem Cell Institute	30
STEM CELL RESEARCH PATENTS AND EFFECT ON STEM CELL MARKETERS	31
Stem Cells via Indirect Lineage Conversion (ILC)	32
COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS	33
<i>TABLE 8 COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS</i>	33
SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS	33
NOVEL MATERIALS	34
GENE THERAPY	34
Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders	35
BIOREACTOR USE IN REGENERATIVE MEDICINE	35
<i>TABLE 9 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE</i>	36
THE IMPACT OF GENOMICS	36
CHAPTER 5 PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE	38
GENE- AND PROTEIN - BASED APPROACHES	38
ANTIBODIES	38
The Importance of Antibody Drugs	39
Advantages of Monoclonal Antibody Drugs	40
Antibodies and Osteoarthritis	40
Denosumab	42
GROWTH FACTORS	42
HOW BMPs FUNCTION	43
<i>TABLE 10 BONE MORPHOGENETIC PROTEINS</i>	44
Clinical Uses	44
Companies	45
CELLS AND TISSUES	46
TISSUE ENGINEERING	46
ARTIFICIAL SKIN	46
CARTILAGE	47
Other Approaches to Cartilage	48
Biosynthetic Composites for Cartilage Repair	49

TOPIC	PAGE NO.
3D Tissue Printing of Cartilage	50
The Market for Tissue-Engineered Cartilage Products	50
<i>TABLE 11 TOTAL U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	50
OTHER PRODUCTS	50
CREATION OF ENTIRE ORGANS	51
EMBRYONIC STEM CELLS	52
NOVEL MATERIALS AND BIOMATERIALS	53
CHAPTER 6 STEM CELL THERAPIES AND REGENERATIVE MEDICINE	56
STEM CELLS AS POTENTIAL REPLACEMENT CELLS	56
OVERALL MARKET AND PARTICIPANTS	57
STEM CELL MARKET RISKS	57
TECHNICAL IMPEDIMENTS	58
OVERVIEW OF FUNDING	58
<i>TABLE 12 FEDERAL FUNDING FOR STEM CELL RESEARCH THROUGH 2012 (\$ MILLIONS)</i>	59
STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH	59
<i>TABLE 13 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH</i>	60
POTENTIAL APPLICATIONS: CURRENT STATUS	60
IN VIVO REPROGRAMMING	61
UMBILICAL CORD BLOOD STEM CELLS	61
Recent Research Developments	62
INDUCED PLURIPOTENT STEM CELLS	62
Recent Research Developments	62
Adult Multipotent Stem Cells	63
Embryonic Stem Cells	63
Adipose Stem Cells for Bone and Joint Applications	65
GERON AND THE FIRST HUMAN TRIALS	66
OTHER STEM CELL RESEARCH	68
STATUS OF OTHER CLINICAL TRIALS	68
STEM CELL THERAPY FOR ALS	69
STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY	70
STEM CELL THERAPY AND BONE MARROW TRANSPLANTS	71
CHAPTER 7 REGENERATIVE PRODUCTS TO TREAT BONE DISEASES	74
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES	74
OSTEOBIOLOGICS	74
BONE GRAFTS	75
PRINCIPAL USES OF BONE GRAFTS	75
<i>TABLE 14 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL</i>	76
<i>TABLE 15 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2018</i>	77
<i>TABLE 16 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2018</i>	77
<i>TABLE 17 BONE GRAFT MATERIALS</i>	78
<i>TABLE 18 SUBSTITUTE BONE GRAFTS</i>	80
AUTOGRAFTS	80

TOPIC	PAGE NO.
BIOSEED GRAFTS	81
ALLOGRAFTS	82
DEMINERALIZED BONE MATRIX PRODUCTS	83
<i>TABLE 19 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX</i>	84
ALLOGRAFT SUPPLIERS	84
Accell	84
AlphaGRAFT	85
Allomatrix	85
Bioset, BioReady	85
Mozaik	85
Grafton DBM	85
DBX	85
DynaBlast and DynaGraft-D	86
Graftech	86
Grafton	86
Opteform	86
OrthoBlast II	87
Osteofil	87
Solo Cervical Allograft	87
XENOGRAFTS	87
THE MARKET FOR ALLOGRAFTS	87
<i>TABLE 20 TOTAL U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2018 (\$ MILLIONS)</i>	88
CELL-BASED BONE GRAFT SUBSTITUTES	88
FACTOR-BASED BONE GRAFT SUBSTITUTES	89
BONE MORPHOGENIC PROTEINS	90
INDUCTOS	91
INFUSE BONE GRAFT	91
OP-1 IMPLANT	92
CERAMIC-BASED BONE GRAFT SUBSTITUTES	92
TYPES OF CERAMICS	93
Alpha-BSM	94
BioActys	94
BioGran	94
Bio-Oss	94
BoneSource	94
Calcigen S	95
Collagraft Strip Bone Graft Matrix	95
Conduit TCP Granules	95
Exabone	95
IsoTis Products	96
Mimix Bone Substitute Material	96
Norian SRS	96
OsteoGraf	97
OsteoMatrix	97
Osteoset	97
OsteoStim Resorbable Bone Graft Substitute	97

TOPIC	PAGE NO.
PerioGlas	97
Pro Osteon Implant	97
Vitoss	98
POLYMER-BASED BONE GRAFT SUBSTITUTES	98
CORTOSS	98
HEALOS	99
IMMIX EXTENDERS AND IMMIX CB	100
THE MARKET FOR BONE GRAFT PRODUCTS	100
<i>TABLE 21 TOTAL GLOBAL MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	100
<i>TABLE 22 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	101
OTHER REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS	101
BIOLOGIC/SYNTHETIC GRAFTS	101
CHRYSALIN	102
NEW SCAFFOLDING TECHNIQUES	103
Honeycomb Implants	103
Electrospun Fiber Multiwell Plates	103
BIOCELLULAR GRAFTS	104
CHAPTER 8 REGENERATIVE APPLICATIONS FOR BONES AND JOINTS	106
MATERIALS FOR BONE TISSUE REPAIR	106
<i>TABLE 23 EXAMPLES OF NANOSTRUCTURED BIOMATERIALS USEFUL IN BONE AND JOINT REGENERATION</i>	107
BIONANOPARTICLES IN BONE HEALING	107
BIODEGRADABLE NANOSCALE FILAMENTS	108
SILK PROTEIN MICROFIBERS	109
INHERENT REGENERATION OF BONE	110
OVERALL SIZE OF BONE GRAFT BUSINESS	110
BONE GRAFT SUBSTITUTES	111
ALLOGRAFT TISSUE	112
OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES	113
HYDROGELS AND REGENERATION	114
HYDROGEL SCAFFOLDING	114
HYDROGEL PATENTS	115
Antimicrobial Nanostructured Hydrogel Web Containing Silver	115
Injectable Peptide Hydrogel That Kills Methicillin-Resistant Staphylococcus Aureus	116
Method to Repair a Damaged Intervertebral Disc Through the Use of a Bioadhesive, Thermogelling Hydrogel	116
Hydrogel Compositions	117
Self-Assembling Protein Hydrogel with Bio-Active Protein	117
Superporous Hydrogel with Cells Encapsulated Therein and Method for Producing the Same	117
Hydrogel Particles	118
Composition and Method for Self-Assembly and Mineralization of Peptide Amphiphiles	118
Chondroitinase Abc I Polynucleotides	119

TOPIC	PAGE NO.
Transdiscal Administration of Cycline Compounds	119
Composition and Method for Preparing Biocompatible Surfaces	119
Spinal Mobility Preservation Apparatus Having an Expandable Membrane	120
MAJOR DISEASES AND CONDITIONS AFFECTING BONES	120
OSTEOPOROSIS	121
Currently Available Products to Treat Osteoporosis	122
Bisphosphonates	122
Fosamax	123
Boniva	124
New Approaches	124
Sclerostin Antibody	124
Romosozumab	124
Probiotics	124
Stem Cell Treatments	125
<i>TABLE 24 DRUGS USED TO TREAT OSTEOPOROSIS</i>	125
Hormones	126
Evista	126
Forteo	126
Miacalcin	128
STEROIDS AND OSTEOPOROSIS	129
Glucocorticoids	129
THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS	130
<i>TABLE 25 GLOBAL MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2018 (\$ MILLIONS)</i>	130
PAGET'S DISEASE	130
DRUGS CURRENTLY AVAILABLE TO TREAT PAGET'S DISEASE	131
Actonel	131
Aredia	131
Skelid	131
Zometa	132
THE MARKET FOR PRODUCTS TO TREAT PAGET'S DISEASE	132
<i>TABLE 26 TOTAL GLOBAL MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2018 (\$ MILLIONS)</i>	132
INJURIES AND DEGENERATIVE CONDITIONS	132
HIP FRACTURES	133
<i>TABLE 27 TOTAL GLOBAL HIP FRACTURE VOLUMES THROUGH 2018</i>	134
<i>TABLE 28 TOTAL U.S. HIP FRACTURE VOLUMES THROUGH 2018</i>	134
TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS	134
<i>TABLE 29 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2012 (%)</i>	134
<i>TABLE 30 U.S. RECONSTRUCTIVE DEVICE MARKET, 2012 (%)</i>	135
MARKET LEADERS	135
JOINT-REPLACEMENT SURGERY	135
<i>TABLE 31 U.S. HIP REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018</i>	136
<i>TABLE 32 HISTORICAL RATES OF HIP REPLACEMENT IN SIX MAJOR STATES, 2001</i>	136
<i>TABLE 33 GLOBAL HIP REPLACEMENT MARKET, THROUGH 2018 (\$ MILLIONS)</i>	136
<i>TABLE 34 TOTAL U.S. HIP REPLACEMENT MARKET, THROUGH 2018 (\$ MILLIONS)</i>	137
KNEE REPLACEMENTS	137

TOPIC	PAGE NO.
VENDORS	137
<i>TABLE 35 TOTAL GLOBAL KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018</i>	138
<i>TABLE 36 TOTAL U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018</i>	138
<i>TABLE 37 TOTAL GLOBAL KNEE REPLACEMENT MARKET THROUGH 20181 (\$ MILLIONS)</i>	138
<i>TABLE 38 TOTAL U.S. KNEE REPLACEMENT MARKET THROUGH 2018 (\$ MILLIONS)</i>	139
<i>TABLE 39 TOTAL U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT THROUGH 2018 (\$ MILLIONS)</i>	139
NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS	139
IMAGING MARKETS AND REGENERATIVE THERAPIES	140
CHAPTER 9 ELECTRICAL BONE GROWTH STIMULATOR MARKET	143
OVERVIEW	143
SCIENTIFIC BASIS	144
ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING	144
MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS	145
BIOMET	145
ORTHOFIX	146
DJO INC.	147
SMITH & NEPHEW (BIOVENTUS)	148
MARKET SIZE	148
<i>TABLE 40 GLOBAL MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2018 (\$ MILLIONS)</i>	148
<i>TABLE 41 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2018 (\$ MILLIONS)</i>	149
R&D - FUTURE PRODUCT POSSIBILITIES	149
CHAPTER 10 ORTHOPEDICS - FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT	152
SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS	152
<i>TABLE 42 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008-2012</i>	153
CHAPTER 11 MARKET FOR TISSUE ENGINEERING PRODUCTS	168
TISSUE ENGINEERING AND CELL THERAPY	168
RESEARCH INITIATIVES	169
NATIONAL INSTITUTES OF HEALTH (NIH)	170
CHAPTER 12 REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY	173
OVERVIEW	173
INDICATIONS AND HISTORY	173
CHARACTERISTICS AND MATERIALS	174
BARRIER MEMBRANES	174
NON-RESORBABLE	174
RESORBABLE	174
COLLAGEN RESORBABLE MEMBRANES	174
SYNTHETIC RESORBABLE MEMBRANES	175
BIOENGINEERED HYBRID TEETH FROM AUTOLOGOUS GUM CELLS	175

TOPIC	PAGE NO.
STEM CELL STUDY RAISES HOPE FOR BONE REPAIR PASTES	176
DENTAL REGENERATIVE PRODUCT VENDORS	177
GEISTLICH PHARMA NORTH AMERICA, INC.	177
ZIMMER	177
ORGANOGENESIS, INC.	177
CHAPTER 13 SKIN TECHNOLOGIES	180
<i>TABLE 43 EXAMPLES OF FDA APPROVED HUMAN SKIN SUBSTITUTES</i>	180
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS	181
<i>TABLE 44 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2018 (\$ MILLIONS)</i>	182
CHAPTER 14 NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE	184
OVERVIEW	184
NEURODEGENERATIVE DISEASES	184
BEST PROSPECTS FOR STEM CELLS IN THIS MARKET	184
STROKE	184
MULTIPLE SCLEROSIS	185
ALZHEIMER'S	185
CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS	186
SPINAL-CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL	187
UNIVERSITY OF SOUTHERN CALIFORNIA (USC)	188
CHAPTER 15 REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE	190
OVERVIEW	190
GENETIC BASIS FOR REGENERATING CELLS AFTER HEART ATTACK	190
STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE	191
PARTICULAR R&D PRIORITIES	191
STEM CELLS AND BIOLOGICAL PACEMAKERS	193
HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS	193
OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART	194
CHAPTER 16 REGENERATIVE MEDICINE AND DIABETES	197
BACKGROUND	197
POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE	197
CLINICAL TRIALS	198
CHAPTER 17 FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE	200
CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS	200
REGULATORY AND LEGAL ENVIRONMENT	200
STATUS OF RESEARCH AND CLINICAL TRIALS	202
ANALYSIS OF CLINICAL TRIALS	203
<i>TABLE 45 REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY (NUMBER/%)</i>	203
<i>TABLE 46 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE STATUS, CONDITIONS AND SPONSOR (AS OF MAY 1, 2013)</i>	204

TOPIC	PAGE NO.
CHAPTER 18 OVERSEAS ACTIVITIES	222
DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES	222
JAPAN	222
Japan Regenerative Therapies Market Prospects	223
<i>TABLE 47 PROJECTED REVENUES OF REGENERATIVE AND TISSUE ENGINEERING MARKETS IN JAPAN, 2009 AND 2020 (\$ MILLIONS)</i>	223
EUROPE	224
REMEDIC	224
Nanobiocom	224
Regenerating Bone Defects Using New Biomedical Engineering Approaches - (REBORNE)	225
Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis - (GAMBA)	225
AUSTRALIA AND CHINA	226
CHAPTER 19 PATENT ANALYSIS	228
ANALYSIS	228
TISSUE ENGINEERING PATENTS	228
<i>TABLE 48 TOP PATENT ASSIGNEES IN TISSUE ENGINEERING FIELD</i>	229
GEOGRAPHIC DISTRIBUTION	229
<i>TABLE 49 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED 1985-2012 (%)</i>	230
RECENT PATENTS	230
TRANSGENIC NON-HUMAN ANIMAL AND METHODS FOR STEM CELL ENGRAFTMENT	230
METHODS FOR MODULATING THE PROLIFERATION AND DIFFERENTIATION POTENTIAL OF STEM CELLS AND PROGENITOR CELLS	230
BIOPOLYMER PRODUCED BY FERMENTING THE EXTRACT OF SOYBEAN WITH FOLIC ACID AND A COMPOSITION CONTAINING THEREOF	231
SUBPOPULATIONS OF BONE MARROW-DERIVED ADHERENT STEM CELLS AND METHODS OF USE THEREFOR	231
COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE	232
REGULATION OF STEM CELL GENE PRODUCTION WITH SPECIFIC AND SELECTIVE ELECTRIC AND ELECTROMAGNETIC FIELDS	232
COMPOSITIONS AND METHODS FOR BONE FORMATION AND REMODELING	233
NEURAL CELL POPULATIONS FROM PRIMATE PLURIPOTENT STEM CELLS	233
OSTEOINDUCTIVE BONE MATERIAL	234
GENES WITH ES CELL-SPECIFIC EXPRESSION	234
USE OF TGF BETA SUPERFAMILY ANTAGONISTS AND NEUROTROPHINS TO MAKE NEURONS FROM EMBRYONIC STEM CELLS	235
HYDROXYPHENYL CROSS-LINKED MACROMOLECULAR NETWORK AND APPLICATIONS THEREOF	235
MAGNETIC CELL AND METHOD OF USING THE SAME	235
DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS	236
ISOLATION AND PRESERVATION OF FETAL HEMATOPOIETIC AND MESENCYMAL SYSTEM CELLS FROM NON-CONTROVERSIAL MATERIALS AND/OR TISSUES RESULTING FROM MISCARRIAGES AND METHODS OF THERAPEUTIC USE	236

TOPIC	PAGE NO.
USE OF TGF BETA SUPERFAMILY ANTAGONISTS TO MAKE DOPAMINERGIC NEURONS FROM EMBRYONIC STEM CELLS	237
DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS	237
METHOD FOR PREPARING NOVEL TRANSCRIPTION FACTORS AND USE	238
ENDODERM CELLS FROM HUMAN EMBRYONIC STEM CELLS	238
GENES WITH ES CELL-SPECIFIC EXPRESSION	238
MARKER SYSTEM FOR PREPARING AND CHARACTERIZING HIGH-QUALITY HUMAN EMBRYONIC STEM CELLS	239
CHAPTER 20 COMPANY PROFILES	241
<i>TABLE 50 PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF MAY 1, 2013</i>	241
<i>TABLE 51 COMPANIES ESTIMATED SALES ATTRIBUTABLE TO REGENERATIVE THERAPIES (BONE AND JOINT), 2012</i>	242
AASTROM BIOSCIENCES INC.	242
ADVANCED CELL TECHNOLOGY INC.	243
AESCULAP INC.	243
ALDAGEN INC.	243
ALPHATEC SPINE INC.	244
ANGIOTECH PHARMACEUTICALS INC.	244
ANIKA THERAPEUTICS INC.	245
APERION BIOLOGICS INC.	245
ARTERIOCYTE MEDICAL SYSTEMS INC.	246
ARTHREX INC.	246
ARTHROCARE CORPORATION	246
AUDAX MEDICAL INC.	247
BAXTER	247
BERKELEY ADVANCED BIOMATERIALS, INC.	248
BIOMATLANTE	248
BIOMET, INC.	249
BIOMIMETIC THERAPEUTICS INC.	249
BIOSURFACE ENGINEERING TECHNOLOGIES (BIOSET)	250
BIOTIME INC.	251
BIOTISSUE TECHNOLOGIES GMBH	252
CAM BIOCERAMICS B.V.	252
CAPSTONE THERAPEUTICS	253
CELLING BIOSCIENCES LLC	253
CENTERPULSE ORTHOPAEDICS INC.	254
CERAPEDICS INC.	254
CITAGENIX INC.	254
CO.DON AG	255
COLLPLANT LTD.	256
CONMED CORPORATION	256
CRYOLIFE, INC.	257
CURASAN AG	258
CURIS	258
CYTOMEDIX INC.	259

TOPIC	PAGE NO.
CYTORI THERAPEUTICS INC.	259
DELENEX THERAPEUTICS AG	260
DEPUY ORTHOPAEDICS INC. (UNIT OF THE DEPUY COMPANIES)	260
DISCGENICS	261
DJO SURGICAL	261
ETEX CORPORATION	262
EXABONE GMBH	262
EXACTECH, INC.	263
FATE THERAPEUTICS INC.	263
GARNET BIOTHERAPEUTICS	264
GEISTLICH PHARMA AG	264
GENZYME BIOSURGERY	265
GERON CORPORATION	265
GRAFTYS	266
HARVARD BIOSCIENCE	266
HISTOGEN	267
INTEGRA LIFESCIENCES HOLDING CORP.	268
INTELLICELL BIOSCIENCES INC.	269
INTERNATIONAL STEM CELL CORPORATION	269
INTERPORE CROSS INTERNATIONAL	270
ISTO TECHNOLOGIES INC.	271
K2M INC.	271
KENSEY NASH CORPORATION	272
KUROS BIOSURGERY AG	273
LIFECCELL	274
MCEWEN CENTRE FOR REGENERATIVE MEDICINE	274
MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE	275
MEDTRONIC INC.	275
MESOBLAST, LIMITED	276
NATIONAL CENTER FOR REGENERATIVE MEDICINE	277
NATIONAL TISSUE ENGINEERING CENTER (NTEC)	278
NEURALSTEM INC.	279
NOVABONE PRODUCTS LLC	280
NOVARTIS CORPORATION	280
NUVASIVE	280
OLYMPUS BIOTECH CORPORATION	281
OPEXA THERAPEUTICS INC.	282
ORGANOGENESIS INC.	282
ORTHOFIX INTERNATIONAL N.V.	283
ORTHOPEUTICS, L.P.	284
ORTHOVITA INC.	284
OSIRIS THERAPEUTICS INC.	285
OSTEOGENICS BIOMEDICAL INC.	285
OSTEOTECH INC.	286
PARCELL LABORATORIES	286
PFIZER INC.	286
PLURISTEM THERAPEUTICS	287

TOPIC	PAGE NO.
PROMOCELL GMBH	287
REGENECURE LTD.	288
REGENTIS BIOMATERIALS LTD.	288
RENEURON	289
REPLACEMENT THERAPY MATERIALS (R.T. MAT.)	289
REPLIGEN CORPORATION	289
ROSLIN CELLAB	290
RTI BIOLOGICS INC.	290
SCIL TECHNOLOGY GMBH	291
SHIRE REGENERATIVE MEDICINE	291
SIGMA-ALDRICH CORPORATION	292
SMITH & NEPHEW	292
STEMCELLS INC.	293
STEMCOR SYSTEMS INC.	293
STRAUMANN USA LLC	294
STRYKER CORP.	294
SYNTHES INC.	294
TEKNIMED	295
TENGION	295
TEPHA INC.	296
TETEC TISSUE ENGINEERING TECHNOLOGIES AG	297
THERMOGENESIS CORP.	297
TIGENIX N.V.	298
UCB S.A. (HEADQUARTERS)	299
VIACYTE INC.	299
WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE	300
WRIGHT MEDICAL GROUP INC.	301
ZIMMER HOLDINGS INC.	301
OTHER ORGANIZATIONS INVOLVED IN REGENERATIVE MEDICINE R&D	302
ACADEMIC INSTITUTIONS	302
U.S. GOVERNMENT	303
OTHER SOCIETIES AND ORGANIZATIONS	303
CHAPTER 21 GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS	306

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR	11
TABLE 2 2012 REVENUES FOR TOP SUPPLIERS OF ORTHOPEDIC PRODUCTS AND MATERIALS (\$ BILLIONS)	12
TABLE 3 TEN PRINCIPAL MARKET DRIVERS (RANKED, MOST SIGNIFICANT TO LEAST SIGNIFICANT)	16
TABLE 4 R&D FOCUSES FOR PRINCIPAL REGENERATIVE MEDICINE	17
TABLE 5 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS	18
TABLE 6 NATIONAL SCIENCE FOUNDATION REGENERATIVE MEDICINE FUNDING PRIORITIES AS OF MAY 1, 2013 (\$)	19
TABLE 7 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2011	27
TABLE 8 COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS	33
TABLE 9 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE	36
TABLE 10 BONE MORPHOGENETIC PROTEINS	44
TABLE 11 TOTAL U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2018 (\$ MILLIONS)	50
TABLE 12 FEDERAL FUNDING FOR STEM CELL RESEARCH THROUGH 2012 (\$ MILLIONS)	59
TABLE 13 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH	60
TABLE 14 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL	76
TABLE 15 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2018	77
TABLE 16 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2018	77
TABLE 17 BONE GRAFT MATERIALS	78
TABLE 18 SUBSTITUTE BONE GRAFTS	80
TABLE 19 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX	84
TABLE 20 TOTAL U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2018 (\$ MILLIONS)	88
TABLE 21 TOTAL GLOBAL MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2018 (\$ MILLIONS)	100
TABLE 22 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, THROUGH 2018 (\$ MILLIONS)	101
TABLE 23 EXAMPLES OF NANOSTRUCTURED BIOMATERIALS USEFUL IN BONE AND JOINT REGENERATION	107
TABLE 24 DRUGS USED TO TREAT OSTEOPOROSIS	125
TABLE 25 GLOBAL MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2018 (\$ MILLIONS)	130
TABLE 26 TOTAL GLOBAL MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2018 (\$ MILLIONS)	132
TABLE 27 TOTAL GLOBAL HIP FRACTURE VOLUMES THROUGH 2018	134
TABLE 28 TOTAL U.S. HIP FRACTURE VOLUMES THROUGH 2018	134
TABLE 29 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2012 (%)	134
TABLE 30 U.S. RECONSTRUCTIVE DEVICE MARKET, 2012 (%)	135

TABLE HEADING	PAGE NO.
TABLE 31 U.S. HIP REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018	136
TABLE 32 HISTORICAL RATES OF HIP REPLACEMENT IN SIX MAJOR STATES, 2001	136
TABLE 33 GLOBAL HIP REPLACEMENT MARKET, THROUGH 2018 (\$ MILLIONS)	136
TABLE 34 TOTAL U.S. HIP REPLACEMENT MARKET, THROUGH 2018 (\$ MILLIONS)	137
TABLE 35 TOTAL GLOBAL KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018	138
TABLE 36 TOTAL U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018	138
TABLE 37 TOTAL GLOBAL KNEE REPLACEMENT MARKET THROUGH 2018 (\$ MILLIONS)	138
TABLE 38 TOTAL U.S. KNEE REPLACEMENT MARKET THROUGH 2018 (\$ MILLIONS)	139
TABLE 39 TOTAL U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT THROUGH 2018 (\$ MILLIONS)	139
TABLE 40 GLOBAL MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2018 (\$ MILLIONS)	148
TABLE 41 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2018 (\$ MILLIONS)	149
TABLE 42 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008-2012	153
TABLE 43 EXAMPLES OF FDA APPROVED HUMAN SKIN SUBSTITUTES	180
TABLE 44 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2018 (\$ MILLIONS)	182
TABLE 45 REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY (NUMBER/%)	203
TABLE 46 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE STATUS, CONDITIONS AND SPONSOR (AS OF MAY 1, 2013)	204
TABLE 47 PROJECTED REVENUES OF REGENERATIVE AND TISSUE ENGINEERING MARKETS IN JAPAN, 2009 AND 2020 (\$ MILLIONS)	223
TABLE 48 TOP PATENT ASSIGNEES IN TISSUE ENGINEERING FIELD	229
TABLE 49 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED 1985-2012 (%)	230
TABLE 50 PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF MAY 1, 2013	241
TABLE 51 COMPANIES ESTIMATED SALES ATTRIBUTABLE TO REGENERATIVE THERAPIES (BONE AND JOINT), 2012	242

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2012-2018 (\$ MILLIONS)	8